Effect of green coffee extract supplementation in patients with type 2 diabetes

Effect of green coffee extract supplementation on glycemic control, insulin resistance, lipid profile, advanced glycation end products, inflammatory and oxidant status in overweight/obese patients with type 2 diabetes : a randomized double-blind clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090203001640N18

Enrollment

Registered

2020-06-14

Start date

2020-09-15

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: Received 400 mg green coffee supplement two times a day orally for two months. Intervention 2: Control group: Placebo group: Received 400 mg starch capsule two tim

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Agreement to participate in the study and completing informed consent form Subjects aged 35-70 years old Body mass index between 25-35 kg/m2 Fasting blood glucose = 126 mg/dl or 2-h plasma glucose =200 mg/dl or treatment with anti-hyperglycemic medications

Exclusion criteria

Exclusion criteria: Following any specific diet in past three months Pregnant and lactating women Insulin treatment

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: At the beginning and end of the study. Method of measurement: Enzymatic /kit.;Plasma insulin. Timepoint: At the beginning and end of the study. Method of measurement: ELISA.;Plasma triglyceride. Timepoint: At the beginning and end of the study. Method of measurement: Enzymatic /kit.;Malondialdehyde. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric.;Carboxymethyl lysine. Timepoint: At the beginning and end of the study. Method of measurement: ELISA.;High-sensitivity C-reactive protein. Timepoint: At the beginning and end of the study. Method of measurement: ELISA.	—

Measure

Time frame

Fasting blood glucose. Timepoint: At the beginning and end of the study. Method of measurement: Enzymatic /kit.;Plasma insulin. Timepoint: At the beginning and end of the study. Method of measurement: ELISA.;Plasma triglyceride. Timepoint: At the beginning and end of the study. Method of measurement: Enzymatic /kit.;Malondialdehyde. Timepoint: At the beginning and end of the study. Method of measurement: Colorimetric.;Carboxymethyl lysine. Timepoint: At the beginning and end of the study. Method of measurement: ELISA.;High-sensitivity C-reactive protein. Timepoint: At the beginning and end of the study. Method of measurement: ELISA.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: At the beginning and end of the study. Method of measurement: Weight in kilograms divided by height in meters squared.;Systolic blood pressure. Timepoint: At the beginning and end of the study. Method of measurement: Mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: At the beginning and end of the study. Method of measurement: Mercury sphygmomanometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvin Mirmiran

Shahid Beheshti University of Medical Sciences

parvin.mirmiran@gmail.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026